Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients

(2010) Vincenzo Cerullo et al.   CANCER RESEARCH

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

(2010) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

(2010) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

(2010) J. D. Dias et al.   CLINICAL CANCER RESEARCH

Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF

(2010) Anniina Koski et al.   MOLECULAR THERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CTLA-4 blockade: therapeutic potential in cancer treatments

(2010) Ahmad Tarhini   OncoTargets and Therapy

Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures

(2009) João D. Dias et al.   EUROPEAN JOURNAL OF CANCER

Adenovirus Virion Stability and the Viral Genome: Size Matters

(2009) Michael A Kennedy et al.   MOLECULAR THERAPY

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

(2008) A. Bashey et al.   BLOOD

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

(2008) Andrew D. Simmons et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation

(2008) J. D. Wolchok et al.   ONCOLOGIST